CDMO– tag –
-
Fujifilm Diosynth Commits $2 Billion to North Carolina Gene Therapy Facility Amid Supply Chain Shifts; India Emerges as Key CDMO Hub
BioSpace Global Overview Fujifilm Diosynth is investing approximately $2 billion in a new gene therapy manufacturing facility in North Carolina, strategically positioning against global supply chain shifts. Catalent, under Novo Holdings,... -
TIDES USA 2026: Oligonucleotide CMC Innovations Address Manufacturing and Analytical Bottlenecks
Informa Connect USA Overview The TIDES USA 2026 summit focused on oligonucleotide CMC (Chemistry, Manufacturing, and Controls) innovations, discussing crucial process, analytical, and CMC strategies for clinical and commercial success. K... -
Lonza Achieves Strong H1 2026 Growth: CDMO Strategy Accelerates with Expanded ADC and High-Value Small Molecule Manufacturing
BioPharma BoardRoom Switzerland Overview Lonza CEO Wolfgang Wienand highlighted the company's strong growth in H1 2026, emphasizing the accelerating momentum of its CDMO strategy. Lonza expanded strategic long-term collaboration agreemen... -
Samsung Biologics Acquires PolyPeptide in All-Cash Offer: Accelerating Multi-Modality Strategy and Global Network Expansion
PR Newswire South Korea Overview Samsung Biologics announced an all-cash offer to acquire PolyPeptide, accelerating its multi-modality strategy and expanding its global manufacturing network across the U.S., Europe, and India. This acqui... -
BeOne Medicines Invests $300M in New Jersey Manufacturing Expansion, Boosting Biologic, Small Molecule, and ADC Production
Fierce Pharma USA Overview BeOne Medicines announced a $300 million investment to significantly expand its manufacturing facility in New Jersey. The Hopewell campus, opened in 2024, will evolve into a fully integrated manufacturing hub, ... -
Lonza and Engitix Ink ADC License Deal for ECM-Targeted Cancer, Fibrosis Therapies
GEN (Genetic Engineering & Biotechnology News) Switzerland Overview Lonza and Engitix Ltd. have signed a licensing agreement for an Antibody-Drug Conjugate (ADC) technology platform, targeting cancer and fibrosis therapies focused on the... -
Hongene Biotech: Scaling Oligonucleotide Manufacturing Crucial for Surging siRNA Demand in Cardiometabolic Diseases
Hongene Biotech China Overview Hongene Biotech emphasizes the critical need for a dramatic scale-up in oligonucleotide manufacturing to meet the surging demand for siRNA therapeutics targeting cardiometabolic diseases. Driven by the succ... -
BioLife Solutions Completes $1 Billion Acquisition to Bolster Cell Therapy Services
RegMedNet USA Overview BioLife Solutions has reportedly completed a $1 billion acquisition, aimed at significantly strengthening its cell therapy service offerings. As a key player in the cell therapy supply chain and manufacturing proce... -
Kincell Bio Scales Allogeneic Cell Therapy Manufacturing, Bridging Early Clinical to Commercial Supply
Kincell Bio USA Overview Kincell Bio, a specialized CDMO for allogeneic cell therapies, is advancing scalable manufacturing solutions to accelerate product commercialization. The company's expertise focuses on developing efficient proces... -
Japan Prioritizes Quality in ‘China Plus One’ CDMO Strategy with Over $4 Billion Investment by FUJIFILM Diosynth and Others
BioProcess International USA Overview A BioProcess International article analyzes the 'China Plus One' strategy and biomanufacturing capacity in the APAC region. FUJIFILM Diosynth Biotechnologies has committed over $4 billion to global e...
